The first and only agent specifically designed for targeted lymphatic mapping and guiding sentinel lymph node biopsy,* LYMPHOSEEK provides accurate and precise lymph node identification in patients with solid tumors.1,2
Discover how LYMPHOSEEK can be used in your facility to provide actionable information that can enhance pathological evaluation and inform patient staging and management decisions.
References: 1. Wallace AM, Hoh CK, Ellner DO, et al. LYMPHOSEEK: A molecular imaging agent for melanoma sentinel node mapping. Ann Surg Oncol. 2007;14:913-21. 2. LYMPHOSEEK Injection [prescribing information]. Dublin, OH: Cardinal Health; June 2017. 3. Sondak V, King DW, Zager JS, et al. Combined analysis of Phase III trials evaluating Tc99m tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2013;20:680-8. 4. Wallace AM, Han LK, Povoski SP, et al. Comparative evaluation of [99mTc] tilmanocept for sentinel lymph node mapping in breast cancer patients: results of two Phase 3 trials. Ann Surg Oncol. 2013; doi 10.1245/s10434-013-2887-8.